Lead Product(s): IMB-150
Therapeutic Area: Urology Product Name: LYT-503
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Imbrium Therapeutics
Deal Size: $59.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 11, 2021
Under the terms of the agreement, Imbrium is responsible for all future development activities and funding for LYT-503/IMB-150, for which an IND filing is planned for early 2022.